In Vitro Drug Susceptibility Testing: Principles, Methods, Standards, and Applications

In vitro drug susceptibility testing is a core laboratory technique that measures how effectively antimicrobial or anticancer agents inhibit the growth of bacteria, fungi, mycobacteria, parasites, or tumor cells under controlled conditions. By determining parameters such as the minimum inhibitory concentration (MIC) and interpreting results against internationally recognized clinical breakpoints, this testing guides targeted therapy, detects emerging resistance, and supports antimicrobial stewardship and drug development. This article provides a comprehensive technical overview of sample types, test items, reference methods, quality standards, and practical applications of in vitro susceptibility testing.

Technical Overview

In vitro drug susceptibility testing, also known as antimicrobial susceptibility testing (AST) when applied to microorganisms, is a standardized laboratory procedure used to evaluate the sensitivity of an isolated pathogen or cell population to specific pharmaceutical agents. The fundamental principle is to expose a defined inoculum of the test organism or cells to a series of drug concentrations under controlled culture conditions, and then to measure growth inhibition quantitatively or semi-quantitatively.

The most important quantitative output is the minimum inhibitory concentration (MIC), defined as the lowest concentration of an antimicrobial agent that prevents visible growth of the microorganism after a standardized incubation period. MIC values are interpreted against clinical breakpoints published by standards organizations such as the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST), categorizing organisms as susceptible (S), intermediate (I) or susceptible-dose dependent (SDD), or resistant (R). When the target is not a microorganism but a population of tumor or primary cells, susceptibility is typically expressed as half-maximal inhibitory concentration (IC50) or viability curves derived from dose-response modeling.

Reference methodologies are codified in international standards, including ISO 20776-1 (broth microdilution reference method for antibacterial testing), ISO 20776-2 (evaluation of susceptibility test devices), and ISO 16256 (broth microdilution reference method for yeasts), together with CLSI documents M02, M07, M11, M24, M27, M38, and M100 and the continuously updated EUCAST breakpoint tables. These frameworks ensure that results generated in accredited third-party laboratories are reproducible, traceable, and clinically actionable.

Testing Samples

Clinical Bacterial Isolates

Pure bacterial cultures recovered from clinical specimens, including blood cultures, urine, sputum, bronchoalveolar lavage fluid, wound and site swabs, cerebrospinal fluid, and sterile body fluids, are the most common samples. Isolates should be freshly subcultured (18 to 24 hours) on appropriate non-selective media, and the inoculum must be standardized to a 0.5 McFarland turbidity standard, corresponding to approximately 1 to 2 × 10⁸ colony-forming units per milliliter, before testing. Mixed or contaminated cultures must be re-isolated before susceptibility testing is performed.

Fungal Isolates

Yeasts such as Candida species and Cryptococcus species, as well as filamentous fungi including Aspergillus, Fusarium, and dermatophytes, can be evaluated for susceptibility to azoles, echinocandins, and polyenes. Fungal suspensions are prepared according to CLSI M27 and M38 procedures, with inoculum quantification by spectrophotometry or hemocytometer counting to meet method-specific optical density targets.

Mycobacterial Cultures

Isolates of Mycobacterium tuberculosis complex and nontuberculous mycobacteria (NTM) are tested against first-line and second-line agents such as isoniazid, rifampicin, ethambutol, fluoroquinolones, and injectables, following CLSI M24 guidance. Because of slow growth, liquid culture-based systems and molecular assays are frequently used in parallel to shorten turnaround time.

Tumor Cells and Primary Cultures

For oncology applications, chemosensitivity testing uses established cell lines, primary tumor cells dissociated from biopsy or surgical specimens, patient-derived xenograft-derived cells, or three-dimensional spheroid and organoid models. Samples must demonstrate adequate viability, typically above 70 percent by trypan blue or fluorescence-based exclusion, and sufficient cell number to support multi-concentration dose-response testing.

Other Organisms and Direct Samples

Phenotypic susceptibility assays are also applied to parasites such as Plasmodium and Leishmania, to viruses for detecting drug resistance in phenotypic plaque-reduction or reporter assays, and to positive blood culture broths for rapid direct susceptibility testing in critical sepsis workflows.

Testing Items

• Minimum inhibitory concentration (MIC) of antibacterial, antifungal, antimycobacterial, or antiparasitic agents
• Minimum bactericidal concentration (MBC) and minimum fungicidal concentration (MFC) for cidal endpoint determination
• Inhibition zone diameters by disk diffusion, reported with categorical interpretation
• Minimum effective concentration (MEC) for echinocandins against filamentous fungi
• Minimum biofilm eradication concentration (MBEC) for biofilm-forming organisms
• Combination synergy testing by checkerboard assay, including fractional inhibitory concentration index (FICI) calculation
• Time-kill kinetic assays to classify static versus cidal activity and evaluate antimicrobial interactions
• Phenotypic resistance mechanism screening, including ESBL, AmpC, and carbapenemase confirmatory tests and inducible clindamycin resistance (D-zone test)
• Categorical interpretation of results as susceptible, intermediate or susceptible-dose dependent, or resistant according to current CLSI or EUCAST breakpoints
• Epidemiological cutoff values (ECOFF/ECV) for delineating wild-type and non-wild-type populations in surveillance programs
• Anticancer drug sensitivity items, including IC50, IC90, maximal inhibition, area under the curve, apoptosis induction, and clonogenic survival

Testing Methods

Broth Microdilution

Broth microdilution is the international reference method described in ISO 20776-1 and CLSI M07. Twofold serial dilutions of the antimicrobial are prepared in cation-adjusted Mueller-Hinton broth within 96-well microtiter plates, inoculated with a standardized suspension, and incubated at 35 ± 2 °C for 16 to 20 hours. The MIC is read as the lowest concentration showing no visible growth, either visually or by automated optical densitometry. This method yields quantitative, highly reproducible results and supports high-throughput panel testing.

Agar Dilution

In agar dilution, antimicrobials are incorporated into molten agar at defined concentrations and a standardized inoculum is spotted onto the surface, allowing multiple isolates to be tested against one agent on a single plate. The method remains a reference technique, particularly for anaerobes under CLSI M11 and for fastidious or slow-growing organisms where broth methods perform poorly.

Disk Diffusion (Kirby-Bauer Method)

Disk diffusion, standardized in CLSI M02 and by EUCAST, applies antimicrobial-impregnated paper disks onto inoculated Mueller-Hinton agar. Following incubation, zone-of-inhibition diameters are measured and interpreted against species-specific breakpoints. The method is cost-effective, flexible in agent selection, and well suited for routine screening, although it provides categorical rather than quantitative concentration endpoints.

Gradient Diffusion Method

Commercially available gradient diffusion strips create a continuous concentration gradient of antimicrobial on agar surfaces. The intersection of the elliptical inhibition zone with the strip yields a direct MIC value, making the technique convenient for confirming borderline MICs, testing fastidious organisms, and evaluating single-drug isolate combinations without preparing dilution series.

Automated and Semi-Automated Systems

Instrumented susceptibility platforms use pre-filled microdilution cards or panels with photometric, fluorometric, or colorimetric detection of growth, generating rapid MIC results, often within 4 to 10 hours for common organisms. Such devices must be validated against the reference method in accordance with ISO 20776-2, and results are interpreted through validated expert software that flags atypical resistance patterns for technician review.

Antifungal Susceptibility Methods

Yeast susceptibility testing follows the CLSI M27 broth microdilution reference method, harmonized with ISO 16256, while filamentous fungi are tested under CLSI M38 and disk diffusion variants under CLSI M44. Endpoints differ by drug class: prominent inhibition for azoles, complete inhibition for Amphotericin B, and minimum effective concentration, reflecting abnormal hyphal growth, for echinocandins against molds.

Mycobacterial Susceptibility Methods

Susceptibility testing of M. tuberculosis complex employs the agar proportion method and validated liquid culture-based systems under CLSI M24, with critical concentrations defining resistance. Molecular line-probe and sequencing assays are increasingly integrated to detect known resistance determinants, and discordant phenotypic results are confirmed by repeat testing or molecular methods.

Time-Kill and Synergy Assays

Time-kill assays, guided by ASTM E2315, monitor viable counts over 24 hours at fixed drug concentrations, with a reduction of three orders of magnitude defining cidal activity. Checkerboard microdilution evaluates drug combinations, calculating the fractional inhibitory concentration index, where FICI values of 0.5 or below indicate synergy, above 4 indicate antagonism, and intermediate values indicate additivity or indifference.

Cell-Based Chemosensitivity Assays

Anticancer susceptibility testing uses colorimetric viability assays such as MTT and WST reduction, ATP-dependent luminescence, real-time impedance monitoring, clonogenic colony formation, and flow-cytometric apoptosis markers. Three-dimensional spheroid and organoid platforms improve physiological relevance, and dose-response curves are fitted by nonlinear regression to derive IC50 values and confidence intervals.

Quality Control and Standards Compliance

Reliable susceptibility results depend on rigorous quality systems. Every analytical run includes certified reference strains from recognized biological standards organizations, such as Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans control strains, with MICs and zone diameters verified against published control ranges. Medium performance, inoculum density, incubation temperature, and atmosphere are monitored continuously.

Accredited third-party laboratories operate under ISO/IEC 17025 quality management systems, participate in external quality assessment and proficiency testing schemes, and trace all critical equipment and reference materials. Test reports must state the method used, the drug panel and MIC values in mg/L, the interpretation category, the breakpoint table and standard applied, and the accompanying quality control results, ensuring full transparency and regulatory defensibility.

Applications

• Clinical guidance: selecting targeted empirical and definitive antimicrobial therapy for bloodstream infections, pneumonia, urinary tract infections, and skin and soft tissue infections
• Antimicrobial stewardship: benchmarking local resistance patterns and de-escalating broad-spectrum therapy in hospitals and long-term care facilities
• Public health surveillance: contributing isolate-level data to national programs and international networks coordinated by organizations such as WHO
• Pharmaceutical research and development: characterizing MIC distributions of new agents, proposing epidemiological cutoff values, and supporting pharmacokinetic-pharmacodynamic breakpoint derivation for regulatory submissions
• Veterinary medicine and aquaculture: monitoring resistance in animal pathogens and zoonotic bacteria and guiding responsible antimicrobial use
• Food safety and environmental monitoring: tracking resistant organisms and resistance genes along the food production chain and in aquatic environments
• Oncology and precision medicine: identifying individual tumor drug response profiles to inform chemotherapy and targeted therapy selection
• Academic research: investigating resistance mechanisms, biofilm tolerance, drug combinations, and novel antimicrobial compounds

FAQ

What is the difference between MIC and MBC?

The MIC is the lowest drug concentration that inhibits visible growth, whereas the MBC is the lowest concentration that kills 99.9 percent of the inoculum, determined by subculturing from no-growth wells onto drug-free agar. A drug is generally considered bactericidal when the MBC is within fourfold of the MIC.

How are susceptible, intermediate, and resistant categories defined?

Clinical breakpoints relate laboratory measurements to therapy. Susceptible indicates a high likelihood of therapeutic success at standard dosing, resistant indicates a high likelihood of failure even at elevated exposure, and intermediate or susceptible-dose dependent implies success is possible with optimized dosing or when the drug concentrates at the infection site.

Which standards govern in vitro susceptibility testing?

The principal frameworks are ISO 20776-1 and ISO 20776-2 for antibacterial testing, ISO 16256 for yeasts, CLSI documents M02, M07, M11, M24, M27, M38, M44, and the annually updated M100 breakpoint tables, and the current EUCAST breakpoint tables. Laboratories select one harmonized system and apply it consistently.

What is the typical turnaround time?

Routine bacterial testing requires approximately 24 hours of incubation after an overnight pure culture is established, so results are commonly available within 48 to 72 hours of specimen receipt. Yeast testing requires 24 to 72 hours depending on species, mold testing up to 96 hours, and phenotypic mycobacterial testing may require one to several weeks, which is why molecular rapid assays are often run in parallel.

Why do CLSI and EUCAST interpretations occasionally differ?

The two organizations derive breakpoints from slightly different datasets, dosing assumptions, and methodology details, so an isolate may be categorized differently in rare cases. Reports must therefore always identify the standard applied, and clinicians should follow the system adopted by their institution.

Can susceptibility testing be performed directly from positive blood cultures?

Yes. Rapid direct inoculation protocols from flagged positive blood culture bottles substantially shorten time to results, particularly when coupled with accelerated automated systems or rapid phenotypic platforms. Direct-test results should be confirmed with standard methods once isolated colonies are available.

How is anticancer drug sensitivity evaluated in vitro?

Tumor cells or organoids are exposed to serial drug concentrations for a defined exposure period, viability is quantified by validated cell viability or ATP-luminescence assays, and dose-response curves are modeled to derive IC50, IC90, and maximal inhibition. Results are interpreted alongside molecular biomarkers to support individualized treatment planning.